Abstract:Abstract Introduction The optimal rectal cancer care is achieved by a multidisciplinary approach, with a high-quality surgical resection, with complete mesorectal excision and adequate margins. New approaches like the transanal total mesorectal excision (TaTME) aim to achieve these goals, maximizing the sphincter preservation ratio, with good oncologic and functional results. This report describes a way to implement TaTME without a proctor, presents the first case series of this approach in a center experienced in rectal cancer, and compares the results with those of the international literature. Methods We performed a retrospective study of the first 10 consecutive patients submitted to TaTME for rectal cancer at our institution. The primary outcomes were postoperative complications, pathological specimen quality and local recurrence rate. The results and performance were compared with the outcomes of a known structured program with proctorship and with the largest meta-analysis on this topic. Results All patients had locally advanced cancer; therefore, all underwent neoadjuvant therapy. A total of 30% had postoperative complications, without mortality or re-admissions. In comparison with the structured training program referred, no differences were found in postoperative complications and reintervention rates, resulting in a similar quality of resection. Comparing these results with those of the largest meta-analysis on the subject, no differences in the postoperative complication rates were found, and very similar outcomes regarding anastomotic leaks and oncological quality of resection were registered. Conclusion The results of this study validate the safety and effectiveness of our pathway regarding the implementation of the TaTME approach, highlighting the fact that it should be done in a center with proficiency in minimally invasive rectal surgery.

Clinical Status and Future Prospects of Transanal Total Mesorectal Excision

The application of laparoscopic total mesorectal excision with preservation of anal sphincter for rectal cancer

[Current status and prospect of transanal total mesorectal excision].

Transanal total mesorectal excision for rectal cancer: hype or new hope?

Transanal Total Mesorectal Excision for Rectal Cancer: a Multicentric Cohort Study.

[Transanal Total Mesorectal Excision in Laparoscopic Surgery for Lower Rectal Cancer: Leading Actor or Supporting Actor].

Evolution of transanal total mesorectal excision for rectal cancer: From top to bottom

Controversies and consensus in transanal total mesorectal excision (taTME): Is it a valid choice for rectal cancer?

Laparoscopic total mesorectal excision versus transanal total mesorectal excision for mid and low rectal cancer: A systematic review and meta-analysis

Futher discussion on the progress and controversy and prospect of the procedure of transanal total mesorectal excision

[Perceptions of transanal total mesorectal excision surgical quality and patient screening]

The advantages and disadvantages of transanal total mesorectal excision

Transanal total mesorectal excision: Understanding indications, managing complications, and effective prevention methods

The role of transanal total mesorectal excision in the treatment of rectal cancer: a systematic review

Transanal Total Mesorectal Excision (tatme) for Rectal Cancer: a Systematic Review and Meta-Analysis of Oncological and Perioperative Outcomes Compared with Laparoscopic Total Mesorectal Excision

Morbidity, Mortality, and Pathologic Outcomes of Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer Short-term Outcomes From a Multicenter Randomized Controlled Trial

Transanal total mesorectal excision for rectal cancer: early outcomes in 50 consecutive patients

Transanal total mesorectal excision (taTME) for cancer located in the lower rectum: short- and mid-term results

A Way to Start Transanal Total Mesorectal Excision for Rectal Cancer

Transanal Total Mesorectal Excision for Rectal Cancer

Transanal total mesorectal excision for low and middle rectal cancer: time for audit?